Higher 25(OH)D3 levels were found to be associated with greater odds of remission with anti-TNF- α agents (adalimumab and infliximab) among patients with IBD in a study by Winter et al. Patients with normal vitamin D levels at the time of anti-TNF-α medication initiation had 2.64 increased odds of remission at three months compared to patients with low vitamin D levels. The gene discussed is TNF; the disease is irritable bowel syndrome.